The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
Nikkei 225 surges over 4% as investors bet on continued stimulus under Japan's likely first female Prime Minister, Sanae Takaichi.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Investors flock to cryptocurrencies, seeking a hedge against a weakening U.S. dollar and a prolonged government shutdown.
Weaker-than-expected jobs data has bolstered investor expectations for another Federal Reserve interest rate cut in October, pushing major indices to record closes.
Investment giant advises 'conservative' allocation to digital assets for certain clients, signaling growing mainstream acceptance.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.